Patents by Inventor Harvey I. Cantor
Harvey I. Cantor has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230383298Abstract: The present disclosure provides, in part, methods of discovering immunotherapy targets in vivo, therapeutic compositions (e.g., shRNA, immunoresponsive cells expressing shRNA and/or a chimeric antigen receptors (CAR)), and methods of use thereof.Type: ApplicationFiled: January 3, 2023Publication date: November 30, 2023Applicants: Dana-Farber Cancer Institute, Inc., The General Hospital Corporation d/b/a Massachusetts General HospitalInventors: Kai W. Wucherpfennig, Glenn Dranoff, Penghui Zhou, Donald Shaffer, Nir Hacohen, Harvey I. Cantor, Diana Alvarez Arias
-
Patent number: 11597934Abstract: The present disclosure provides, in part, methods of discovering immunotherapy targets in vivo, therapeutic compositions (e.g., shRNA, immunoresponsive cells expressing shRNA and/or a chimeric antigen receptors (CAR)), and methods of use thereof.Type: GrantFiled: November 24, 2020Date of Patent: March 7, 2023Assignees: DANA FARBER CANCER INSTITUTE, INC., THE GENERAL HOSPITAL CORPORATIONInventors: Kai W. Wucherpfennig, Glenn Dranoff, Penghui Zhou, Donald Shaffer, Nir Hacohen, Harvey I. Cantor, Diana Alvarez Arias
-
Publication number: 20210139914Abstract: The present disclosure provides, in part, methods of discovering immunotherapy targets in vivo, therapeutic compositions (e.g., shRNA, immunoresponsive cells expressing shRNA and/or a chimeric antigen receptors (CAR)), and methods of use thereof.Type: ApplicationFiled: November 24, 2020Publication date: May 13, 2021Applicants: Dana-Farber Cancer Institute, Inc., The General Hospital Corporation d/b/a Massachusetts General HospitalInventors: Kai W. Wucherpfennig, Glenn Dranoff, Penghui Zhou, Donald Shaffer, Nir Hacohen, Harvey I. Cantor, Diana Alvarez Arias
-
Patent number: 10876120Abstract: The present disclosure provides, in part, methods of discovering immunotherapy targets in vivo, therapeutic compositions (e.g., shRNA, immunoresponsive cells expressing shRNA and/or a chimeric antigen receptors (CAR)), and methods of use thereof.Type: GrantFiled: April 3, 2018Date of Patent: December 29, 2020Assignees: DANA-FARBER CANCER INSTITUTE, INC, THE GENERAL HOSPITAL CORPORATIONInventors: Kai W. Wucherpfennig, Glenn Dranoff, Penghui Zhou, Donald Shaffer, Nir Hacohen, Harvey I. Cantor, Diana Alvarez Arias
-
Publication number: 20180327750Abstract: The present disclosure provides, in part, methods of discovering immunotherapy targets in vivo, therapeutic compositions (e.g., shRNA, immunoresponsive cells expressing shRNA and/or a chimeric antigen receptors (CAR)), and methods of use thereof.Type: ApplicationFiled: April 3, 2018Publication date: November 15, 2018Applicants: Dana-Farber Cancer Institute, Inc., The General Hospital Corporation d/b/a Massachusetts General HospitalInventors: Kai W. Wucherpfennig, Glenn Dranoff, Penghui Zhou, Donald Shaffer, Nir Hacohen, Harvey I. Cantor, Diana Alvarez Arias
-
Patent number: 9944931Abstract: The present disclosure provides, in part, methods of discovering immunotherapy targets in vivo, therapeutic compositions (e.g., shRNA, immunoresponsive cells expressing shRNA and/or a chimeric antigen receptors (CAR)), and methods of use thereof.Type: GrantFiled: June 10, 2014Date of Patent: April 17, 2018Assignees: Dana-Farber Cancer Institute, Inc., The General Hospital CorporationInventors: Kai W. Wucherpfennig, Glenn Dranoff, Penghui Zhou, Donald Shaffer, Nir Hacohen, Harvey I. Cantor, Diana Alvarez Arias
-
Publication number: 20160122766Abstract: The present disclosure provides, in part, methods of discovering immunotherapy targets in vivo, therapeutic compositions (e.g., shRNA, immunoresponsive cells expressing shRNA and/or a chimeric antigen receptors (CAR)), and methods of use thereof.Type: ApplicationFiled: June 10, 2014Publication date: May 5, 2016Inventors: Kai W. Wucherpfennig, Glenn Dranoff, Penghui Zhou, Donald Shaffer, Nir Hacohen, Harvey I. Cantor, Diana Alvarez Arias
-
Patent number: 5238839Abstract: The present invention relates to genes and their encoded proteins which induce immunological effector cell activation and chemattraction. The proteins of the invention attract subsets of immunological effector cells and stimulate them to express their specialized effector cell functions. Such proteins, termed Ap-1 proteins, are expressed by lymphoid cells, and bind to effector cells such as macrophages and mast cells. In particular, the ApPursuant to the provisions of 35 U.S.C. .sctn.202(c), it is hereby acknoledged that the Governament has certain rights in this invention, which was made in part with funds from the National Institutes of Health.Type: GrantFiled: July 18, 1991Date of Patent: August 24, 1993Assignee: Dana Farber Cancer InstituteInventors: Harvey I. Cantor, Roberto Patarca, Joel L. Schwartz, Gordon Freeman
-
Patent number: 5149785Abstract: The present invention is directed to genes, termed Rpt-1 (regulatory protein T lymphocyte-1), which are expressed at higher levels by resting CD4.sup.+ helper/inducer T cells relative to activated CD4.sup.+ cells. The invention also relates to the proteins encoded by such genes, termed rpt-1 proteins, which regulate gene expression directed by the promoter region of the interleukin-2 receptor (IL-2r) alpha chain gene or by the promoter region of the long terminal repeat of human lymphotropic retroviruses such as the human immunodeficiency virus type 1 (HIV-1), human T cell leukemia virus (HTLV-I, and HTLV-II. In particular, rpt-1 proteins down-regulate gene expression controlled by the promoter of the IL-2r alpha chain gene or by the promoter of the long terminal repeat of HIV-1. The proteins and nucleic acids of the invention have value in diagnosis and therapy of immune disorders such as AIDS.Type: GrantFiled: February 21, 1990Date of Patent: September 22, 1992Assignee: Dana-Farber Cancer InstituteInventors: Harvey I. Cantor, Roberto Patarca, Gordon J. Freeman
-
Patent number: 5049659Abstract: The present invention relates to genes and their encoded proteins which induce immunological effector cell activation and chemattraction. The proteins of the invention attract subsets of immunological effector cells and stimulate them to express their specialized effector cell functions. Such proteins, termed Ap-1 proteins, are expressed by lymphoid cells, and bind to effector cells such as macrophages and mast cells. In particular, the Ap-1 proteins induce macrophage phagocytosis, expression of class II major histocompatibility molecules, cytotoxicity, and migration, and induce hematopoietic progenitor cell differentiation. The Ap-1 molecules can be of value in the therapy or diagnosis of inflammatory or immune disorders, or neoplasia.Type: GrantFiled: February 9, 1988Date of Patent: September 17, 1991Assignee: Dana Farber Cancer InstituteInventors: Harvey I. Cantor, Roberto M. Patarca, Joel L. Schwartz
-
Patent number: 4952499Abstract: The present invention is directed to genes, termed Rpt-1 (regulatory protein T lymphocyte-1), which are expressed at higher levels by resting CD4.sup.+ helper/inducer T cells relative to activated CD4.sup.+ cells. The invention also relates to the proteins encoded by such genes, termed rpt-1 proteins, which regulate gene expression directed by the promoter region of the interleukin-2 receptor (IL-2r) alpha chain gene or by the promoter region of the long terminal repeat of human lymphotropic retroviruses such as the human immunodeficiency virus type 1 (HIV-1) human T cell leukemia virus (HTLV)-I, and HTLV-II. In particular, rpt-1 proteins down-regulate gene expression controlled by the promoter of the IL-2r alpha chain gene or by the promoter of the long terminal repeat of HIV-1. The proteins and nucleic acids of the invention have value in diagnosis and therapy of immune disorders such as AIDS.Type: GrantFiled: February 11, 1988Date of Patent: August 28, 1990Assignee: Dana-Farber Cancer InstituteInventors: Harvey I. Cantor, Roberto Patarca
-
Patent number: 4722998Abstract: The present invention is directed to a method of producing growth factors for mammalian cells. More particularly, the method of the present invention comprises isolating mammalian inducer T-lymphocytes, and stimulating growth factor production by contacting these inducer lymphocytes with an antigen or a mitogen. The resulting growth factors are then separated from the material produced by the stimulated lymphocytes.Type: GrantFiled: June 5, 1986Date of Patent: February 2, 1988Assignee: Dana Farber Cancer InstituteInventors: Harvey I. Cantor, Gary Nabel
-
Patent number: 4720482Abstract: The present invention is directed to a pharmaceutical composition, comprising a mammalian cell growth factor and a pharmaceutically acceptable carrier. The growth factor of the present invention is selected from the group comprising;(a) a protein having a molecular weight of about 14 kilodaltons and being functional to stimulate growth of both B and T lymphocytes;(b) a protein having an apparent molecular weight of about 50 kilodaltons and being functional to stimulate growth of B lymphocytes; and(c) a growth factor having an apparent mean molecular weight of about 45 kilodaltons and being funtional to stimulate growth of mast cells.Type: GrantFiled: June 5, 1986Date of Patent: January 19, 1988Assignee: Dana Farber Cancer InstituteInventors: Harvey I. Cantor, Gary Nabel
-
Patent number: 4613459Abstract: A family of growth factors, methods of making and using such growth factors in in vivo treatment of living mammalian cells, and products incorporating such growth factors, are disclosed.The growth factors were isolated from the supernatant fluid obtained by incubation of inducer T-cells in the presence of a suitable antigen or mitogen. The growth factors disclosed include a 14 Kd polypeptide which stimulates growth of both T-cells and B-cells, a 50 Kd polypeptide which stimulates B-cells to multiply and secrete immunoglobulins, and a 45 Kd growth factor which stimulates secretion of immunoglobulins by B-cells and stimulates rapid growth of certain mast cells, stem cells and certain other types of cells.Type: GrantFiled: October 20, 1982Date of Patent: September 23, 1986Assignee: Dana-Farber Cancer InstituteInventors: Harvey I. Cantor, Gary Nabel
-
Patent number: 4559310Abstract: The present invention is directed to an in vitro assay, useful in determining the effectiveness of anti-allergy compounds and/or useful in measuring the degree of sensitivity of a patient to particular allergens.The present invention permits potential anti-allergy agents to be assayed in a number of ways. For example, the binding and dissociation rates of IgE to the mast cells in the presence and the absence of the substance being tested may be measured thereby giving a direct indication of that substance's ability to interfere with the IgE binding reaction. Another measure of a substance's potential as an anti-allergy agent is based upon the release of mediators or other compounds from the mast cells after sensitization by the allergen and exposure of the sensitized cells to the allergen.Type: GrantFiled: May 20, 1983Date of Patent: December 17, 1985Assignee: Dana Farber Cancer InstituteInventors: Harvey I. Cantor, Gary Nabel